{"id":"W2159877301","doi":"10.1002/pbc.25454","title":"Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2","year":2015,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Chemoimmunotherapy; Induction chemotherapy; Chemotherapy; Oncology; Internal medicine; Regimen; Cog; Minimal residual disease; Chemotherapy regimen; Bone marrow; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002354978,0.001029427,0.001402207,0.0004818566,0.0002274362,0.0006612666,0.001074105,0.0008248621,0.001243163],"category_scores_gemma":[0.0008889011,0.0002972171,0.0006782027,0.0004092219,0.0006228787,0.0004138014,0.0003470843,0.002231734,0.0003609336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009693927,"about_ca_system_score_gemma":0.001137326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001143678,"about_ca_topic_score_gemma":0.001671002,"domain_scores_codex":[0.999305,0.0003818027,0.00003672621,0.00008180806,0.00008487835,0.0001097348],"domain_scores_gemma":[0.9991577,0.0002197483,0.0001532247,0.0001199188,0.00005476613,0.0002946683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4500628,0.1028781,0.03287458,0.001276707,0.002538872,0.0006351712,0.0006178612,0.005701062,0.1095014,0.0003882898,0.007524603,0.2860006],"study_design_scores_gemma":[0.3271584,0.554737,0.0624826,0.00008959708,0.001247503,0.00133376,0.00006664763,0.001748885,0.04112758,0.000143893,0.009822351,0.00004177075],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948961,0.002580564,0.0003938203,0.0002002372,0.00003676579,0.0006100943,0.0004304265,0.00005810397,0.0007937534],"genre_scores_gemma":[0.9859589,0.003530391,0.00234445,0.0006403691,0.0001781685,0.001242576,0.004610769,0.00005638359,0.001437996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002354978,"threshold_uncertainty_score":0.01245445,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02528339772203831,"score_gpt":0.3236444405717604,"score_spread":0.2983610428497221,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}